Can Europe's Approval And Value Reviews Work More In Concert? It's A Timesaver That Might Be A Long Time Coming
In recent years, European drug approval agencies and health technology assessment authorities had little interchange, reflecting mutual disregard at best, and mutual recrimination at worst, European Medicines Agency Senior Medical Officer Hans-Georg Eichler observed.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
The pharmaceutical industry is edging closer to EU-wide clarity on how the bloc’s data privacy rules can be applied consistently to clinical trials and pharmacovigilance activities.
Some medicines may be subject to price rises that make them unaffordable if the burden of paying for extra wastewater treatment is not more fairly distributed across different industries, the Danish pharmaceutical industry association has warned.
The European Medicines Agency is bringing back in-person oral explanation meetings with drug sponsors on a pilot basis, following industry feedback that direct engagement with its scientific committees is highly valued.
Vinay Prasad’s exit from the US FDA reignited conversations about integrating its drugs and biologics centers under George Tidmarsh. Those plans appear to be shelved, but the leadership transition could be an opportunity to fully realize the vision for the Oncology Center of Excellence.
The Pink Sheet viewed Stealth's complete response letter and other documents indicating the FDA appears willing to grant accelerated approval to elamipretide before a confirmatory trial begins enrolling. But the company says it needs a two-month review of the NDA resubmission to survive.